Drugs / GORIVITUG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05293678 | Apr 2022 → Jan 2023 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GORIVITUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314615 ↗ |
| Known as | REGN15160 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05293678 ↗ |
| Modality | Monoclonal antibody | “Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies” NCT05293678 ↗ |
| Route | Intravenous | “Administered in single intravenous (IV) dose” NCT05293678 ↗ |